BioCryst Pharma (BCRX) Informed by FDA Clinical Hold on BCX 4161 Removed
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Up)Join SI Premium – FREE
On July 31, 2013, BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) was notified by the United States Food and Drug Administration (“FDA”) that the Clinical Hold placed on its hereditary angioedema drug BCX 4161 has been removed. The FDA notified BioCryst that the Complete Response submitted by BioCryst to address the Clinical Hold satisfactorily addressed the FDA’s concerns. This notification by the FDA provides BioCryst the ability to initiate BCX 4161 clinical trials in the United States and/or include U.S. clinical sites in its BCX 4161 clinical trials.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Day One Biopharmaceuticals' (DAWN) OJEMDA receives FDA approval.
- enVVeno Medical (NVNO) Reports Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from VenoValve
- BioNano Genomics (BNGO) Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
Create E-mail Alert Related Categories
FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
